Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
 FORM 8-K
 ______________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 28, 2016
 ______________________________
 
 
 
 
 
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________
 
 
 
 
 
Colorado
 
001-35647
 
90-0224471
(State or other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
9785 S. Monroe Street, Suite 300, Sandy, UT 84070
(Address of Principal Executive Offices and Zip Code)
 
 
 
 
 
Registrant’s telephone number, including area code: (801) 432-9000
______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

    




 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
Item 8.01.
Other Events.

As previously disclosed, on September 29, 2016, LifeVantage Corporation (the “Company”) received a notice from The NASDAQ Stock Market LLC (“Nasdaq”) stating that because it had not received the Company’s Form 10-Q for the period ended September 30, 2016, and because the Company remains delinquent in filing its Form 10-K for the fiscal year ended June 30, 2016 (the "Initial Delinquent Filing"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The notices from Nasdaq stated that the Company had until November 28, 2016 to submit a plan to regain compliance with Nasdaq’s continued listing requirements.
On November 28, 2016, the Company timely submitted its plan to Nasdaq detailing how the company will regain compliance with Nasdaq’s continued listing requirements ("Compliance Plan").
If the Compliance Plan is accepted, Nasdaq may grant the Company an extension of up to 180 calendar days from the original non-compliance date of September 28, 2016, or until March 27, 2017, to regain compliance. The Company's common stock will continue to trade on the Nasdaq Capital Market pending Nasdaq's review of the Compliance Plan.
On November 28, 2016, the Company issued a press release announcing the submission of the Compliance Plan. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

   
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits

Exhibit
 
Description
 
 
99.1
 
Press Release dated November 28, 2016



    




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
Date: November 28, 2016
LIFEVANTAGE CORPORATION

By: /s/ Beatryx Washington
Name: Beatryx Washington
Title: Senior Vice President of Legal Affairs





    

Exhibit
https://cdn.kscope.io/c3e236b11cdb14a798bfd87b1b4c94dc-nasdaqcomplianceplanp_image1.jpg



LifeVantage Submits Plan With Nasdaq To Regain Compliance


SALT LAKE CITY, UT, November 28, 2016 – LifeVantage Corporation (Nasdaq: LFVN) announced today that it has submitted its plan to Nasdaq detailing how the company will regain compliance with continued listing requirements.

On September 29, 2016, LifeVantage received a letter from Nasdaq indicating that the company was not in compliance with Listing Rule 5250(c)(1), due to the company's inability to file its Form 10-K for fiscal year 2016 by the extended date deadline. And, on November 15, 2016, LifeVantage received an additional non-compliance letter from Nasdaq due to the company’s inability to file its Form 10-Q for the quarter ended September 30, 2016 by the filing deadline.

If the plan is accepted, Nasdaq may grant LifeVantage an extension of up to 180 calendar days from the original non-compliance date of September 28, 2016, or until March 27, 2017, to regain compliance. The company's common stock will continue to trade on the Nasdaq Capital Market pending Nasdaq's review of the plan of compliance.

About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), is a science-based network marketing company dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim® Nrf2 and NRF1 Synergizers, our line of scientifically-validated dietary supplements, the TrueScience® Anti-Aging Skin Care Regimen, Canine Health®, the AXIO® energy product line and the PhysIQ™ smart weight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.

Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates", "look forward to", "goal", “may be”, and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our plan to regain compliance with Nasdaq listing rules and any extension period that may be granted by Nasdaq, the timing of our release of earnings information and the filing of our Form 10-K and Form 10-Q. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the final conclusions of the Audit Committee (and the timing of such conclusions) concerning the matters discussed above, including revenue, tax or other implications resulting from any accounting adjustments or other factors, and those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.


Investor Relations Contact:




https://cdn.kscope.io/c3e236b11cdb14a798bfd87b1b4c94dc-nasdaqcomplianceplanp_image1.jpg


Cindy England
Director of Investor Relations
(801) 432-9036
investor@lifevantage.com

-or-

Scott Van Winkle
Managing Director, ICR
(617) 956-6736
scott.vanwinkle@icrinc.com
Media Relations Contact:
John Genna
Vice President of Communications
& Corporate Partnerships
(801) 432-9172
jgenna@lifevantage.com